Press release
Human Immunodeficiency Virus Type 1 (HIV-1) Market to Set Phenomenal Growth From 2025 to 2034
Human Immunodeficiency Virus Type 1 (HIV-1) Market
Human Immunodeficiency Virus Type 1 (HIV-1) remains the most common and widespread form of HIV infection, responsible for the global HIV/AIDS epidemic. Despite decades of progress, HIV-1 continues to affect over 38 million people worldwide, with Sub-Saharan Africa carrying the highest burden.
While no definitive cure has yet been achieved, advances in antiretroviral therapy (ART), long-acting injectables, preventive therapies (PrEP), and gene-editing technologies are reshaping the market. Increasing awareness, supportive global health programs, and significant biopharmaceutical investment are expected to fuel steady market expansion over the next decade.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71726
Market Overview
The global HIV-1 market was valued at USD 29.5 billion in 2024 and is projected to reach USD 47.2 billion by 2034, growing at a CAGR of 4.8% during the forecast period.
Key Highlights
• Market Size 2024: Estimated at USD 29.5 billion
• Forecast 2034: Expected to reach USD 47.2 billion
• CAGR (2025-2034): 4.8%
Market Drivers
• Growing adoption of long-acting injectable therapies improving patient adherence.
• Expanding global access to ART through government and NGO programs.
• Increasing uptake of preventive strategies such as pre-exposure prophylaxis (PrEP).
• Rising investments in gene-editing and curative research.
Market Challenges
• Lifelong treatment requirement and high drug costs.
• Stigma associated with HIV/AIDS leading to underdiagnosis.
• Unequal global access, with developing regions struggling to afford advanced therapies.
Leading Players
Key companies in the HIV-1 market include Gilead Sciences, ViiV Healthcare (GlaxoSmithKline, Pfizer, Shionogi), Johnson & Johnson (Janssen), Merck & Co., AbbVie, Roche, Moderna, Bristol Myers Squibb, and Cipla Ltd.
Segmentation Analysis
By Product
• Antiretroviral Therapy (ART) - NRTIs, NNRTIs, PIs, INSTIs
• Long-Acting Injectables
• Pre-Exposure Prophylaxis (PrEP) Drugs
• Monoclonal Antibodies
• Gene Therapy & RNA-Based Candidates
By Technology
• Oral Therapy
• Injectable / Long-Acting Therapy
• Gene Editing / RNAi Platforms
By End Use
• Hospitals
• Specialty Clinics
• Research Institutes
• Homecare Settings
By Application
• HIV-1 Treatment
• HIV-1 Prevention (PrEP)
• Opportunistic Infection Management
• Curative Therapy Research
Summary:
ART remains the cornerstone of HIV-1 treatment, but long-acting injectables and PrEP therapies are expected to grow rapidly. Emerging gene therapies and monoclonal antibodies hold transformative potential, although still in early clinical development.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71726/human-immunodeficiency-virus-type-1-hiv-1-market
Regional Analysis
• North America
Largest market, with widespread ART adoption, robust R&D, and availability of advanced therapies. The U.S. leads in innovation with strong government support through programs like PEPFAR.
• Europe
Strong second, driven by comprehensive healthcare systems, high awareness, and robust HIV prevention campaigns. Germany, the UK, and France dominate the region.
• Asia-Pacific
Fastest-growing region due to large patient pools in India and China, government programs for HIV management, and expanding access to generics. Japan is also contributing through innovative R&D.
• Middle East & Africa
Home to the highest prevalence, particularly in Sub-Saharan Africa. Despite limited resources, international funding from NGOs and WHO initiatives are driving market growth.
• Latin America
Moderate growth, with Brazil and Mexico leading through national ART distribution programs and rising use of preventive therapies.
Regional Summary:
North America and Europe lead revenues, while Asia-Pacific and Africa represent the largest patient bases and fastest-growing opportunities, fueled by public health investments and increased generic adoption.
Market Dynamics
Key Growth Drivers
• Expansion of global HIV/AIDS programs ensuring wider treatment access.
• Breakthroughs in long-acting and once-monthly injectables improving compliance.
• Rising focus on preventive measures such as PrEP and post-exposure prophylaxis (PEP).
• Investment in curative technologies such as CRISPR gene editing.
Key Challenges
• Treatment affordability and inequitable access in developing regions.
• Stigma and social barriers limiting patient engagement in care.
• Need for lifelong adherence to ART, increasing the risk of resistance.
Latest Market Trends
• Launch of cabotegravir-based injectables for PrEP and treatment.
• Exploration of broadly neutralizing antibodies (bNAbs) as potential therapies.
• Development of therapeutic vaccines to enhance immune response.
• Expansion of telemedicine and digital adherence tools to support HIV patients.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71726
Competitor Analysis
Major Players
• Gilead Sciences - Global leader in HIV therapies with products like Biktarvy and Truvada (PrEP).
• ViiV Healthcare (GSK, Pfizer, Shionogi) - Known for Cabenuva, the first long-acting injectable therapy.
• Johnson & Johnson (Janssen) - Developer of rilpivirine-based therapies and vaccine research.
• Merck & Co. - Advancing novel HIV prevention therapies and integrase inhibitors.
• AbbVie - Strong pipeline in HIV drug combinations.
• Roche & Moderna - Researching monoclonal antibodies and mRNA-based HIV vaccines.
• Bristol Myers Squibb - Active in immunotherapy and HIV research.
• Cipla Ltd. - Major generic manufacturer improving ART affordability worldwide.
Competitive Landscape Summary:
The HIV-1 market is characterized by intense competition between established leaders like Gilead and ViiV Healthcare, while emerging biotechs focus on vaccines and curative strategies. The shift toward long-acting therapies and prevention tools is reshaping market dynamics.
Conclusion
The Human Immunodeficiency Virus Type 1 (HIV-1) market is set to grow from USD 29.5 billion in 2024 to USD 47.2 billion by 2034, at a CAGR of 4.8%. Growth is fueled by long-acting injectables, PrEP therapies, and ongoing research into curative technologies.
Although affordability and stigma remain barriers, the global outlook is optimistic as governments, NGOs, and pharmaceutical companies continue to prioritize HIV/AIDS elimination goals.
Outlook:
North America and Europe will remain leading revenue markets, but Asia-Pacific and Africa will be the true drivers of global impact, due to their large patient populations and growing access programs. Companies that focus on affordable innovation, equitable access, and patient-friendly delivery models will define the future of the HIV-1 therapeutics market.
This report is also available in the following languages : Japanese (ヒト免疫不全ウイルス1型(HIV-1)市場), Korean (인간 면역 결핍 바이러스 1형(HIV-1) 시장), Chinese (人类免疫缺陷病毒 1 型(HIV-1)市场), French (Marché du virus de l'immunodéficience humaine de type 1 (VIH-1)), German (Markt für das humane Immundefizienzvirus Typ 1 (HIV-1)), and Italian (Mercato del virus dell'immunodeficienza umana di tipo 1 (HIV-1)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71726
Our More Reports:
BRIC Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72350/bric-hernia-repair-devices-market
Asia-Pacific Surgical Energy Devices Market
https://exactitudeconsultancy.com/reports/72351/asia-pacific-surgical-energy-devices-market
EU5 Surgical Energy Devices Market
https://exactitudeconsultancy.com/reports/72352/eu5-surgical-energy-devices-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Immunodeficiency Virus Type 1 (HIV-1) Market to Set Phenomenal Growth From 2025 to 2034 here
News-ID: 4177665 • Views: …
More Releases from Exactitude Consultancy
Niemann-Pick Disease Type C (NPC) Market to Reach USD 610 Million by 2034
Niemann-Pick Disease Type C (NPC) is a rare, progressive, neurodegenerative lysosomal storage disorder caused by mutations in the NPC1 or NPC2 genes. These mutations impair intracellular cholesterol and lipid transport, leading to accumulation in the brain, liver, and spleen. Clinical manifestations include ataxia, cognitive decline, hepatosplenomegaly, vertical gaze palsy, and progressive neurological impairment.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71713
NPC is often called "childhood Alzheimer's" because of its…
Seasonal Influenza Market 2025-2034 Business Outlook, Critical Insight and Growt …
Introduction
Seasonal influenza, commonly known as the flu, is an acute viral infection caused by influenza viruses A and B. It remains one of the most widespread infectious diseases, responsible for millions of severe cases and hundreds of thousands of deaths worldwide every year. The virus's ability to mutate rapidly requires annual vaccination campaigns and ongoing updates to vaccine composition.
The Seasonal Influenza market is shaped by continuous public health initiatives, pharmaceutical…
Von Hippel-Lindau (VHL) Disease Market to Reach USD 890 Million by 2034
Von Hippel-Lindau (VHL) disease is a rare, inherited genetic disorder caused by mutations in the VHL tumor suppressor gene. It predisposes individuals to the development of multiple benign and malignant tumors across various organs, including the kidneys, pancreas, adrenal glands, retina, and central nervous system. The most life-threatening complications include renal cell carcinoma (RCC), pheochromocytomas, and central nervous system hemangioblastomas.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71711
Although…
Hereditary Transthyretin Amyloidosis (hATTR) Market is expected to reach USD 9.2 …
Hereditary transthyretin amyloidosis (hATTR) is a rare, progressive, life-threatening disease caused by mutations in the TTR gene, leading to the misfolding of transthyretin protein and deposition of amyloid fibrils in nerves, heart, and other organs. Patients typically present with polyneuropathy, cardiomyopathy, autonomic dysfunction, and gastrointestinal issues, making it a highly complex condition.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71709
Historically underdiagnosed and undertreated, hATTR has seen a revolution in…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
